Mersana Therapeutics (MRSN) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts MRSN Hot Sheet
Join SI Premium – FREE
Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.75 million versus the consensus estimate of $6.05 million.
For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ericsson (ERIC) Tops Q2 EPS by 3c
- RBC Capital Starts Denison Mines (DML:CN) (DNN) at Outperform
- Barclays Downgrades Unicaja (UNI:SM) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
